Prostatype Genomics Ab Stock Profit Margin
| PROGEN Stock | SEK 7.50 0.15 1.96% |
Prostatype Genomics AB fundamentals help investors to digest information that contributes to Prostatype Genomics' financial success or failures. It also enables traders to predict the movement of Prostatype Stock. The fundamental analysis module provides a way to measure Prostatype Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prostatype Genomics stock.
Prostatype |
Prostatype Genomics AB Company Profit Margin Analysis
Prostatype Genomics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Prostatype Genomics AB has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Diagnostics & Research industry. The profit margin for all Sweden stocks is 100.0% lower than that of the firm.
Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Prostatype Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (23.61) % | |||
| Current Valuation | 20.62 M | |||
| Shares Outstanding | 22.86 M | |||
| Shares Owned By Insiders | 1.00 % | |||
| Shares Owned By Institutions | 13.47 % | |||
| Price To Book | 1.14 X | |||
| Price To Sales | 34.59 X | |||
| Revenue | 10 K | |||
| Gross Profit | (5.98 M) | |||
| EBITDA | (15.46 M) | |||
| Net Income | (15.63 M) | |||
| Cash And Equivalents | 7.66 M | |||
| Cash Per Share | 0.58 X | |||
| Total Debt | 866.67 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (16.08 M) | |||
| Earnings Per Share | (1.22) X | |||
| Target Price | 21.02 | |||
| Beta | 1.22 | |||
| Market Capitalization | 42.29 M | |||
| Total Asset | 40.2 M | |||
| Z Score | 28.8 | |||
| Net Asset | 40.2 M |
About Prostatype Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prostatype Genomics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prostatype Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prostatype Genomics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.